INO 1800

Drug Profile

INO 1800

Alternative Names: INO-1800; INO-1800 SynCon® immunotherapy; RG-7944

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 15 Mar 2017 Inovio Pharmaceuticals completes enrolment in its phase I trial for Hepatitis B in USA, Australia, Hong Kong, New Zealand, Philippines, Puerto Rico, Singapore, Taiwan and Thailand
  • 03 Aug 2016 Roche terminates its exclusive licence agreement for the development of INO 1800
  • 01 Mar 2015 The FDA approves IND application for INO 1800 in Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top